ADH1A and melanoma: In line with pre‐clinical studies in melanoma using ADH‐1, our dynamic BLI studies using D‐luciferin in the C57BL/KaLwRij/5TGM1 MM mouse model suggests that LCRF‐0006 similarly increases the permeability of tumor‐associated vasculature to molecules with high binding affinity for plasma proteins.